UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-09974 ENZO BIOCHEM, INC. | --- | --- | |------------------------------------------------ ...

Enzo Biochem, Inc. (ENZ) delivered a loss per share of 19 cents from continuing operations in fiscal 2024, narrower than the loss of 51 cents per share in the comparable fiscal 2023 period. Enzo Biochem's Revenues in Detail Enzo Biochem's Life Sciences Products reporting unit operates in one reportable segment, Products. The company's Products revenues were $7.5 million in the fiscal fourth quarter, down 16% year over year. This was due to a shift in ordering patterns. The company's Products revenues were $ ...

Exhibit 99.1 Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights ● The Company's revenues ...

FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock. Full Year Highlights The Company's revenues in the 2024 period of $31.9 million improved year-over-year by 3%. Enzo's sales to its industrial customers ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-09974 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) | --- | --- | --- | |-------- ...

ViktorCap If you're a shareholder of Enzo Biochem (NYSE:ENZ), you're likely frustrated. The investment thesis hasn't changed much in two years; however, shareholders, have been bludgeoned by one thing after another while awaiting Enzo's liquidation following their 2023 sale of the Clinical Labs business to Labocrp Holdings (LH). Is it finally time to buy the beaten-down story, or are investors better off avoiding this mess? There are multiple activists involved in the stock, and the new chairman brings a tr ...

Enzo Biochem, headquartered in Farmingdale, NY, has carved a niche in molecular diagnostics. It provides an extensive array of technical platforms and reagent sets for biomedical research and translational science. The company's Life Science division supports a diverse range of applications, including cell biology and genomics, among others. The company maintains a robust balance sheet with $57.2 million in cash as of the fiscal third quarter, despite a reduction due to a significant paydown of accounts pay ...

Core Insights - Enzo Biochem, Inc. reported a loss per share of 4 cents from continuing operations in Q3 of fiscal 2024, an improvement from a loss of 16 cents per share in the same quarter last year [1] - The company achieved a net loss of $2.1 million from continuing operations, significantly narrower than the $7.9 million loss reported in the prior year [6] - The gross profit increased by 24.1% to $3.7 million, with gross margin expanding by 633 basis points to 46.5% [21] Revenue Analysis - Total revenues for the Asia Pacific segment were $0.9 million, reflecting a 15.4% increase year-over-year [3] - The Europe segment generated revenues of $2.4 million, up 39.8% year-over-year, attributed to increased marketing efforts in drug development product sales [14] - Products revenues reached $8 million in Q3, marking a 7.2% increase year-over-year, driven by strong performance in Europe and Asia Pacific [13][14] Expense Management - Selling, general and administrative expenses decreased by 27.9% to $4.5 million [4] - Research and development expenses fell by 31.6% year-over-year to $0.6 million [4] - Adjusted operating expenses totaled $5.1 million, down 28.4% year-over-year [4] Profitability Metrics - Adjusted EBITDA for the quarter was a loss of $1.2 million, an improvement from the loss of $3.6 million in the previous year [16] - Adjusted operating loss was $1.4 million, narrower than the adjusted operating loss of $4.1 million reported a year ago [22] Liquidity and Debt - Cash and cash equivalents at the end of Q3 were $57.2 million, down from $60.2 million at the end of Q2 [11] - Total debt at the end of Q3 was $2.7 million, slightly down from $2.8 million at the end of Q2 [23] - Cumulative net cash used in operating activities increased to $25.2 million from $19.9 million a year ago [17] Strategic Developments - The company launched an enhanced website with e-commerce functionality aimed at improving customer access to products and support, which is expected to positively impact stock performance [24]

FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced financial results for the fiscal third quarter ended April 30, 2024. The Company's Life Science division's third-quarter revenue of $8.0 million improved year-over-year by 7%, marking four consecutive quarters of revenue growth compared to the prior year quarterly periods. Revenue for the nine months ended April 30, 2024 of $24.4 million improved 10% compared to the same year-to-date ...

Revenue Performance - Product revenues increased to $8.0 million in the 2024 period, up 7% from $7.5 million in the 2023 period, with a 40% revenue increase in European markets[133] - Product revenues increased to $24.4 million in the 2024 period, up 10% from $22.1 million in the 2023 period, driven by a 10% increase in the US market and a 16% increase in the European market[146] Profitability - The gross profit margin for Products improved to approximately 47% in the 2024 period from 40% in the 2023 period, driven by a favorable product mix and lower input costs[134] - The cost of product revenues decreased to $13.0 million in the 2024 period, a reduction of 5% from $13.7 million in the 2023 period, resulting in a gross profit margin improvement to approximately 47%[147] Expenses - Research and development expenses decreased by 32% to $0.6 million in the 2024 period from $0.9 million in the 2023 period, with no activities related to translational research due to exiting the clinical reference business[135] - Research and development expenses were reduced to $2.0 million in the 2024 period, down 25% from $2.7 million in the 2023 period, following the cessation of translation product development[148] - Selling, general and administrative expenses fell by 28% to $4.5 million in the 2024 period from $6.2 million in the 2023 period, primarily due to reduced consulting fees and lower salaries[136] - Selling, general and administrative expenses decreased to $16.6 million in the 2024 period, a decline of 3% from $17.1 million in the 2023 period, primarily due to lower consulting fees and reduced salaries[149] - Legal and related expenses decreased by 84% to $0.7 million in the 2024 period from $4.3 million in the 2023 period, reflecting reduced legal needs following the Asset Purchase Agreement[137] - Legal and related expenses significantly decreased to $2.5 million in the 2024 period, down 59% from $6.2 million in the 2023 period, reflecting reduced legal needs[150] Interest and Financial Adjustments - Interest income increased to $0.7 million in the 2024 period compared to a net interest expense of $0.1 million in the 2023 period, a favorable variance of $0.8 million[138] - Interest income increased to $2.6 million in the 2024 period, a favorable variance of $2.5 million compared to $0.1 million in the 2023 period, due to net proceeds from the Asset Purchase Agreement[151] - The company recorded a fair value adjustment charge of approximately $0.4 million for the Debentures as of April 30, 2024[139] Foreign Exchange Impact - The foreign exchange loss for the Products segment was $0.5 million in the 2024 period, compared to a gain of $0.4 million in the 2023 period, resulting in an unfavorable variance of $0.9 million[140] - The foreign exchange loss for the 2024 period was approximately $0.9 million, compared to a gain of $1.0 million in the 2023 period, resulting in an unfavorable variance of $1.9 million[153] Cash Flow and Financial Position - As of April 30, 2024, the company's cash and cash equivalents totaled $57.2 million, down from $83.4 million as of July 31, 2023, primarily due to net losses and cash used to pay down liabilities[154] - Net cash used in operating activities was $25.2 million in the 2024 period, an increase of $5.3 million compared to $19.9 million in the 2023 period, attributed to the paydown of accounts payable[155] Legal Matters - A ransomware attack in April 2023 affected approximately 2,470,000 individuals' clinical test information, with potential costs covered up to $3 million by the company's cybersecurity insurance[128] - The company is involved in ongoing legal matters, including class action lawsuits related to a ransomware attack, which may impact future financial obligations and profitability[157] Business Transactions - The company completed the sale of its Clinical Services business to Labcorp for an aggregate purchase price of $113.25 million in cash, effective July 24, 2023[125]